U.S., Dec. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07260708) titled 'Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers' on Nov. 20.
Brief Summary: This is a Phase I clinical study aimed at evaluating the safety and pharmacokinetics of TQB2922 subcutaneous injection in patients with advanced cancers.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Cancers
Intervention:
DRUG: TQB2922 injection (subcutaneous injection)
TQB2922 is a bispecific antibody against Epidermal Growth Factor Receptor (EGFR)/c-Met.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Lt...